

Dear Colleague:

The Consumer Healthcare Products Association (CHPA), on behalf of the leading makers of over-the-counter (OTC) cough and cold medicines, would like to provide you with additional information regarding FDA's announcements today concerning oral pediatric cough and cold medicines.

While the agency's announcement urging parents not to use these medicines in children under the age of two was expected and is not new information, FDA's recommendation does underscore that our voluntary withdrawal of these medicines in October 2007—taken out of an abundance of caution since infants are especially vulnerable to accidental misuse—was the correct course of action.

In addition to the voluntary withdrawal of the "infant" oral OTC cough and cold medicines, the leading makers of these medicines have begun the process of developing and implementing necessary labeling changes on oral cough and cold medicines intended for older consumers. This effort is aimed at discouraging parents and other caregivers from giving infants medication intended for older children or adults.

While this relabeling process may take a while and as we work with FDA to resolve outstanding labeling issues concerning children two-years-old and over, we already have developed educational materials to help you communicate valuable safe medicine use tips to your customers. These tips include:

1. Always read and follow the label.
2. Always give the recommended dose and use the measuring device provided.
3. Do not use oral cough and cold medicines in children under two.
4. Never give two medicines with any of the same active ingredients.
5. Only give the medicine that treats your child's specific symptoms.
6. If your child develops any side effects or reactions that concern you, stop use of the OTC medicine and contact your doctor immediately.
7. Do not give a medicine only intended for adults to a child.
8. Never use an OTC medicine to sedate a child.

9. Keep all medicines out of your child's reach and sight.
10. Consult a doctor, pharmacist, or other healthcare professional with any questions.

Please visit www.OTCsafety.org for more information. The print-production files of our educational brochure also are available for cobranding and distribution to your customers.

For additional information on today's [FDA's announcement](#) or to view [CHPA's press release](#), please visit www.chpa-info.org.

We will keep you apprised of any developments.

Regards,

Linda Suydam, D.P.A.

President

CHPA